NASDAQ:RGC Regencell Bioscience Q4 2026 Earnings Report $7.11 -0.24 (-3.27%) Closing price 04:00 PM EasternExtended Trading$7.12 +0.01 (+0.21%) As of 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Regencell Bioscience EPS ResultsActual EPS-$0.01Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ARegencell Bioscience Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ARegencell Bioscience Announcement DetailsQuarterQ4 2026Date10/7/2026TimeAfter Market ClosesConference Call DateWednesday, October 7, 2026Conference Call Time4:00PM ETConference Call ResourcesAnnual Report (20-F)Earnings HistoryCompany ProfilePowered by Earnings DocumentsAnnual report(20-F) Regencell Bioscience Earnings HeadlinesRegencell Bioscience (NASDAQ:RGC) Stock Jumps 0.3% - Time to Buy?October 1, 2026 | americanbankingnews.comRegencell Bioscience: I Got It Wrong (Rating Downgrade)September 23, 2026 | seekingalpha.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.October 7 at 1:00 AM | Profits Run (Ad)RGC Resources: More Likely To Appeal More To Income-Focused InvestorsAugust 18, 2026 | seekingalpha.comRegencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-KJuly 3, 2026 | theglobeandmail.comRegencell Bioscience surges on apparent short squeezeJuly 1, 2026 | msn.comSee More Regencell Bioscience Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Regencell Bioscience? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Regencell Bioscience and other key companies, straight to your email. Email Address About Regencell BioscienceRegencell Bioscience (NASDAQ:RGC) is a clinical-stage biotechnology company focused on developing traditional Chinese medicine (TCM) treatments for neurocognitive disorders and degenerative conditions. Its research has centered primarily on conditions such as dementia and attention-deficit/hyperactivity disorder (ADHD), with the goal of developing herbal formulations that may address underlying symptoms and disease-related challenges. The company’s product development programs include proprietary TCM formulations intended for neurological and cognitive conditions. Regencell has also conducted research involving formulations for other health conditions, but its principal strategic focus has been on treatments for dementia and ADHD. These products remain investigational and are subject to clinical development and applicable regulatory requirements. Regencell was established in 2014 and is based in Hong Kong, where it conducts its research and development activities. The company is led by Yat-Gai Au, who serves as its chief executive officer and has been associated with Regencell’s development since its early operations. Regencell Bioscience Holdings Limited trades on the Nasdaq Capital Market under the symbol RGC.View Regencell Bioscience ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Skydance Just Became a Media Giant—With an $80 Billion Debt LoadPenguin Solutions Is Soaring as AI Memory Demand ExplodesWall Street Is Betting These 3 Beaten-Down Stocks Have More Room to RunLamb Weston’s Turnaround Is Starting to Look RealRPM International’s Dividend King Status Just Got StrongerAI Chip Demand Gives Linde a New Growth CatalystAllient’s Data Center and Defense Momentum Is Raising the Stakes Upcoming Earnings PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026)Wells Fargo & Company (10/13/2026)Johnson & Johnson (10/13/2026)UnitedHealth Group (10/13/2026)Bank of America (10/14/2026)BlackRock (10/14/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
